EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Bernard Combe(Université de Montpellier), Hasan Yazıcı(Yeditepe University Hospital), R. B. M. Landewé(Maastricht University), Alan J. Silman(Nuffield Orthopaedic Centre), Paul Emery(University of Leeds), Cédric Lukas(Centre National de la Recherche Scientifique), Gianfranco Ferraccioli(Università Cattolica del Sacro Cuore), Lars Klareskog(Karolinska University Hospital), Henning B. Nielsen(University of Copenhagen), Maxime Dougados(Délégation Paris 5), F. C. Breedveld(Leiden University Medical Center), H D Boloşiu, Josef S Smolen(Leiden University Medical Center), E. Martín‐Mola(Hospital Universitario La Paz), J. M. W. Hazes(Erasmus University Rotterdam), Klaus Machold(Medical University of Vienna)
Cited by 798
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k
A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination
|Arthritis & Rheumatism|2005|1.5k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k